Scholar Rock Holding Corp (NAS:SRRK)

$ 9.43 -0.4 (-4.07%) Market Cap: 752.08 Mil Enterprise Value: 605.68 Mil PE Ratio: 0 PB Ratio: 4.12 GF Score: 55/100

Scholar Rock Holding Corp at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Q3 2023 Scholar Rock Holding Corp Earnings Call Transcript
Nov 07, 2023

$12.35 (+1.48%)

Earnings
Scholar Rock Holding Corp Overview of the Current Treatment Landscape and Unmet Needs of Patients with SMA Transcript
Jul 12, 2023
Scholar Rock Holding Corp at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Scholar Rock Holding Corp TOPAZ Phase 2 Clinical Trial Data Transcript
Jun 17, 2022
Scholar Rock Holding Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Scholar Rock Holding Corp at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 09, 2021
Scholar Rock Holding Corp to Host KOL Discussing Apitegromab's Therapeutic Potential in Patients with SMA Call Transcript
Jun 15, 2021
Scholar Rock Holding Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021
Scholar Rock Holding Corp Annual Shareholders Meeting Transcript
May 27, 2021
Scholar Rock Holding Corp to Announce the 12-Month Top-line Results of TOPAZ Phase 2 Trial Transcript
Apr 06, 2021
Scholar Rock Holding Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Scholar Rock Holding Corp to Discuss the SRK-015 TOPAZ Interim Analysis Results Conference Call Transcript
Oct 27, 2020
Scholar Rock Holding Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020
Q2 2020 Scholar Rock Holding Corp Earnings Call Transcript
Aug 07, 2020

$14.07 (+2.25%)

Earnings
Scholar Rock Holding Corp Annual Shareholders Meeting Transcript
May 29, 2020
Scholar Rock Holding Corp at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019
Scholar Rock Holding Corp at Oppenheimer Healthcare Conference Transcript
Mar 19, 2019
Scholar Rock Holding Corp at Cowen Health Care Conference Transcript
Mar 13, 2019
Scholar Rock Holding Corp SRK-015 Interim Phase 1 Results and Phase 2 Trial Design Conference Call Transcript
Feb 26, 2019

Scholar Rock Holding Corp Overview of the Current Treatment Landscape and Unmet Needs of Patients with SMA Transcript

Jul 12, 2023 / 01:00PM GMT

Release Date Price: $7 (-6.29%)

Transcript

Rushmie Nofsinger

Good morning. I'm Rushmie Nofsinger, Vice President of Corporate Affairs and Investor Relations at Scholar Rock. Welcome, and thank you for joining us today for our virtual investor event on apitegromab's potential to advance the standard of care for patients with spinal muscular atrophy or SMA. The webcast slides can be accessed on the Events and Presentations section of the Investor Relations page on the Scholar Rock website.

Before we begin, I want to note that we'll be making various statements about Scholar Rock's expectations, plans and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by any forward-looking statements as a result of various important factors more fully discussed in the section titled Risk Factors in our quarterly report on Form 10-Q as well as other important factors in Scholar Rock's future filings with the Securities and Exchange Commission. Any forward-looking statements represent our views

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.